Edition:
United States

Novartis AG (NVS)

NVS on New York Consolidated

84.85USD
26 Jul 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$84.85
Open
--
Day's High
--
Day's Low
--
Volume
100
Avg. Vol
2,127,679
52-wk High
$86.90
52-wk Low
$66.93

Summary

Name Age Since Current Position

Joerg Reinhardt

61 2013 Independent Non-Executive Chairman of the Board

Joseph Jimenez

57 2010 Chief Executive Officer, Member of the Executive Committee

Enrico Vanni

66 2013 Independent Non-Executive Vice Chairman of the Board

Harry Kirsch

51 2013 Chief Financial Officer, Member of the Executive Committee

Michael Ball

2016 Chief Executive Officer of Alcon, Member of the Executive Committee

James Bradner

2016 President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive Committee

Richard Francis

48 2014 Chief Executive Officer of Sandoz Division, Member of the Executive Committee

Paul Hudson

2016 Chief Executive Officer of Novartis Pharmaceuticals, Member of the Executive Committee

Bruno Strigini

2016 Chief Executive Officer of Novartis Oncology, Member of the Executive Committee

Felix Ehrat

60 2012 Group General Counsel, Member of the Executive Committee

Steven Baert

42 2014 Head of Human Resources, Member of the Executive Committee

Vasant Narasimhan

2016 Global Head of Drug Development and Chief Medical Officer for Novartis, Member of the Executive Committee

Andre Wyss

48 2014 Member of the Executive Committee, President of Novartis Business Services and Country President for Switzerland

Charlotte Pamer-Wieser

2011 Corporate Secretary

Nancy Andrews

59 2015 Non-Executive Independent Director

Dimitri Azar

58 2012 Non-Executive Independent Director

Ton Buechner

52 2016 Non-Executive Independent Director

Srikant Datar

63 2003 Non-Executive Independent Director

Elizabeth Doherty

60 2016 Non-Executive Independent Director

Ann Fudge

65 2008 Non-Executive Independent Director

Pierre Landolt

70 1996 Non-Executive Independent Director

Charles Sawyers

58 2013 Non-Executive Independent Director

Andreas von Planta

61 2006 Non-Executive Independent Director

William Winters

55 2013 Non-Executive Independent Director

Samir Shah

2013 Global Head Investor Relations

Biographies

Name Description

Joerg Reinhardt

Mr. Joerg Reinhardt, Ph.D. is Independent Non-Executive Chairman of the Board of Novartis Inc. since August 2013. He is Chairman of the Chairman's Committee. Dr. Reinhardt previously served as chairman of the board of management and the executive committee of Bayer HealthCare. Prior to that, he served as Chief Operating Officer of Novartis from 2008 to 2010, and as Head of the Vaccines and Diagnostics Division of Novartis from 2006 to 2008. He also served as Chairman of the Board of the Genomics Institute of the Novartis Research Foundation in the United States from 2000 to 2010; as a member of the supervisory board of MorphoSys AG in Germany from 2001 to 2004; and as a member of the board of directors of Lonza Group AG in Switzerland from 2012 to 2013. He is currently a member of the Council of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). Dr. Reinhardt graduated with a Ph.D. in pharmaceutical sciences from Universitaet des Saarlandes, Saarbruecken. He joined Sandoz Pharma Ltd. in 1982 and held various positions including Head of Development. Following the merger that created Novartis in 1996, Dr. Reinhardt became Head of Preclinical Development and Project Management at Novartis, and assumed the position of Head of Pharmaceutical Development in 1999. His leadership, Global and Industry experience include being former chairman of global healthcare company; former Chief Operating Officer of Novartis and former Chairman of Novartis research institution; former board member of biotechnology company; former board member of global supplier for pharmaceutical, healthcare, and life sciences industries; member of global non-profit representing pharmaceutical industry.

Joseph Jimenez

Mr. Joseph S. Jimenez is Chief Executive Officer and Member of the Executive Committee of Novartis Inc. since February 1, 2010. Prior to that, he served as CEO - Pharmaceuticals Division as of October 2007. In the Company he is responsible for heading the Company's diversified healthcare portfolio of innovative pharmaceuticals, generics, vaccines and diagnostics and consumer health products. Previously, Mr. Jimenez served as Division Head, Novartis Pharmaceuticals. Mr. Jimenez joined Novartis in April 2007 as Division Head, Novartis Consumer Health. Previously, he served as President and Chief Executive Officer (CEO) of the North America business for the H.J. Heinz Company and as President and CEO of Heinz in Europe from 2002 to 2006. Prior to joining Novartis, he was a Non-Executive Director of Astra-Zeneca plc, United Kingdom, from 2002 to 2007. He was also an advisor for the private equity organization Blackstone Group in the United States. Mr. Jimenez is Member of the Board of Directors of Colgate-Palmolive. He graduated with a bachelors degree from Stanford University in 1982 and with a Master of Business Administration (MBA) degree from the University of California, Berkeley, in 1984.

Enrico Vanni

Dr. Enrico Vanni, Ph.D. is Independent Non-Executive Vice Chairman of the Board at Novartis Inc. since February 22, 2013. He was Member of the Board of Directors at Novartis AG since 2011 till February 22, 2013. He qualifies as an Independent Non-Executive Director. He is Member of the Audit and Compliance Committee, and Chairman of the Compensation Committee at the Company. He began his career as a research engineer at International Business Machines Corp. in California, and joined McKinsey & Company in Zurich, Switzerland, in 1980. He managed the Geneva office for McKinsey from 1988 to 2004, and consulted for companies in the pharmaceutical, consumer and finance sectors. He led its European pharmaceutical practice and served as Member of the Partner review committee of the firm prior to his retirement in 2007. Since his retirement as Director of McKinsey & Company in 2007, Dr. Vanni has been an independent consultant. He is currently Member of several Boards of Directors in industries from healthcare to private banking, for nonlisted companies including Eclosion2, Denzler & Partners SA and Banque Privee BCP (Suisse) SA. Dr. Vanni holds an engineering degree in chemistry from Ecole polytechnique federale de Lausanne (the Federal Polytechnic School of Lausanne), Switzerland, a Ph.D. in chemistry from Universite de Lausanne, as well as a Master of Business Administration from INSEAD in Fontainebleau, France.

Harry Kirsch

Mr. Harry Kirsch is Chief Financial Officer and Member of the Executive Committee of Novartis Inc. since May 1, 2013. Mr. Kirsch joined Novartis in 2003 and previously served as Chief Financial Officer of the Company’s Pharmaceuticals Division. At Novartis, he also served as Chief Financial Officer of Pharma Europe, and as Head of Business Planning & Analysis and Financial Operations for the Pharmaceuticals Division. Mr. Kirsch joined Novartis from Procter & Gamble (P&G) in the United States, where he was CFO of P&G's global pharmaceuticals business. Prior to that, he held finance positions in different categories of P&G's consumer goods business, technical operations, and Global Business Services organization. Mr. Kirsch studied industrial engineering and economics at the Universitaet Karlsruhe in Germany (Diplom Wirtschaftsingenieur).

Michael Ball

Mr. Michael (Mike) Ball is Chief Executive Officer of Alcon, Member of the Executive Committee of Novartis Inc. February 1, 2016. Previously, he served as CEO of Hospira from 2011 to 2015. At Hospira, a world leader in injectable pharmaceuticals and infusion devices, he successfully turned the company around and grew it by focusing on product and quality improvements, and expanding its global footprint. Prior to Hospira, Mr. Ball held a number of senior leadership positions at Allergan, beginning in 1995. He served as president from 2006 to 2011 after having led the strategy and execution of global commercial activities for a wide range of businesses, including eye care pharmaceuticals, over-the-counter products and surgical devices. Before joining Allergan, Mr. Ball held roles of increasing responsibility in marketing and sales at Syntex Corporation and Eli Lilly. He began his career in the healthcare industry in 1981.

James Bradner

Mr. James (Jay) Bradner, M.D. is President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive Committee of Novartis Inc. March 1, 2016. Prior to joining Novartis, Dr. Bradner was on the faculty of Harvard Medical School in the Department of Medical Oncology at the Dana-Farber Cancer Institute in the United States. He was also associate director of the Center for the Science of Therapeutics at the Broad Institute of MIT and Harvard. Dr. Bradner is a co-founder of five biotechnology companies and has co-authored more than 150 scientific publications and 30 US patent applications.

Richard Francis

Mr. Richard Francis is Chief Executive Officer of Sandoz Division, Member of the Executive Committee at Novartis Inc. since May 1, 2014. Most recently, Mr. Francis was the senior vice president of the company’s US commercial organization. Prior to this he served at Biogen Idec, where he held global and country leadership positions. From 1998 to 2001, Mr. Francis was at Sanofi in the United Kingdom, where he held various marketing roles across the company’s urology, analgesics and cardiovascular products. He also has held sales and marketing positions at Lorex Synthelabo and Wyeth. He holds a B.A. in economics from the Manchester Metropolitan University, England.

Paul Hudson

Mr. Paul Hudson is Chief Executive Officer of Novartis Pharmaceuticals, Member of the Executive Committee of Novartis Inc. since July 1, 2016. He joined Novartis from AstraZeneca, where he most recently was president, AstraZeneca United States and executive vice president, North America. He also served as representative director and president of AstraZeneca K.K. in Japan; as president of AstraZeneca’s business in Spain; and as vice president and primary care director, United Kingdom. Before AstraZeneca, Mr. Hudson held roles of increasing responsibility at Schering-Plough, including leading biologics global marketing. He began his career in sales and marketing roles at GlaxoSmithKline UK and Sanofi-Synthélabo UK.

Bruno Strigini

Mr. Bruno Strigini is Chief Executive Officer of Novartis Oncology, Member of the Executive Committee of Novartis Inc. since July 1, 2016. He joined Novartis in 2014 as President of Oncology. Prior to Novartis, he was president of MSD for Europe and Canada (Merck & Co. in the United States and Canada). He previously worked at Schering-Plough, UCB Celltech and SmithKline Beecham, and his roles included president of international operations, president of Japan and Asia-Pacific, head of global marketing and business development, and managing director positions.

Felix Ehrat

Dr. Felix R. Ehrat, Ph.D., is Group General Counsel and Member of the Executive Committee of Novartis Inc. since January 1, 2012. He joined the Company in October 2011 as General Counsel and a permanent attendee of the Executive Committee. Dr. Ehrat is a practitioner of corporate, banking, and mergers and acquisitions law, as well a in corporate governance and arbitration. He started his career as an associate with Baer & Karrer Ltd. in Zurich in 1987, became Partner in 1992, and advanced to Senior Partner (2003 to 2011) and Executive Chairman of the Board (2007 to 2011) of the firm. Dr. Ehrat is Chairman of Globalance Bank AG in Switzerland, and Member of the Board of Liechtensteinische Landesbank AG in Liechtenstein. Previously, Dr. Ehrat was Chairman of Banca del Gottardo, and a Board Member of Julius Baer Holding AG, Austriamicrosystems AG, Charles Voegele Holding AG, and Carlo Gavazzi Holding AG. Mr. Ehrat was admitted to the Zurich bar in 1985 and received his doctorate of law from Universitaet Zuerich (the University of Zurich) in 1990. In 1986, he completed an LL.M. at McGeorge School of Law in the United States. His past memberships and positions include: the International Bar Association, where he was co-chair of the Committee on Corporate and M&A Law from 2007 to 2008; Association Internationale des Jeunes Avocats, where he was president from 1998 to 1999; and the Swiss Arbitration Association, the Zurich Bar Association, and the Swiss Bar Association.

Steven Baert

Mr. Steven Baert has been Head of Human Resources, Member of the Executive Committee of Novartis Inc. since February 26, 2014. Mr. Baert joined Novartis in 2006 as Head of Human Resources Global Functions in Switzerland. He also served as Head of Human Resources, United States and Canada, for Novartis Pharmaceuticals Corporation. Prior to joining Novartis, Mr. Baert held positions in human resources for Bristol-Myers Squibb and Unilever.

Vasant Narasimhan

Mr. Vasant (Vas) Narasimhan, M.D. is Global Head of Drug Development and Chief Medical Officer for Novartis, Member of the Executive Committee of Novartis Inc. since February 1, 2016. He joined Novartis in 2005 and has held numerous leadership positions in development and commercial functions. His most recent role was Global Head of Development for Novartis Pharmaceuticals, overseeing the entire general medicines pipeline. He previously served as Global Head of the Sandoz Biopharmaceuticals and Oncology Injectables business unit, overseeing the division’s biosimilars pipeline, and as Global Head of Development for Novartis Vaccines. Dr. Narasimhan has also held commercial and strategic roles at Novartis, including North America Region Head for Novartis Vaccines, and United States Country President for Novartis Vaccines and Diagnostics. Before joining Novartis, he worked at McKinsey & Company.

Andre Wyss

Mr. Andre Wyss has been Member of the Executive Committee, President of Novartis Business Services and Country President for Switzerland at Novartis Inc. since July 1, 2014. Previously, he was Global Head of Novartis Business Services (NBS) since May 1, 2014 till July 1, 2014. previously he served as US Country Head and President of Novartis Pharmaceuticals Corporation. Prior to that, he served as Head of the Pharmaceuticals Division Region Asia-Pacific, Middle East and African Countries (AMAC). Before leading AMAC, he served as Group Emerging Markets Head, and as Country President and Head of Pharmaceuticals, Greece. Mr. Wyss received a graduate degree in economics from the School of Economics and Business Administration (HWV).

Charlotte Pamer-Wieser

Ms. Charlotte Pamer-Wieser, Ph.D. serves as Corporate Secretary at Novartis Inc. since September 2011. In 2004, Ms. Pamer-Wieser started her professional career as associate at Walder Wyss Ltd., in Zurich, Switzerland. From 2007 to 2011, she worked as senior associate for Bär & Karrer Ltd. in Zurich. Her areas of specialization include corporate law, mergers and acquisitions, company reorganizations and banking and finance law. Ms. Pamer-Wieser received a Ph.D. from the Universitaet Basel, Switzerland, and holds a master’s degree in law (LL.M.) from the University of Chicago Law School. In 2002, she was admitted to the Basel bar, and from 2007 to 2010 she was a lecturer at the University of Basel. Ms. Pamer-Wieser has written several articles on corporate law and is a member of the “Association des Jeunes Avocats” (aija) and the American Law and Economics Association.

Nancy Andrews

Ms. Nancy C. Andrews is Non-Executive Independent Director of Novartis Inc. since February 27, 2015. She is a member of the Research & Development Committee at the company. Dr. Andrews is dean of the Duke University School of Medicine and vice chancellor for academic affairs at Duke University in the United States. She is also a professor of pediatrics, pharmacology and cancer biology at Duke. Prior to joining Duke, she was director of the Harvard/MIT M.D.-Ph.D. Program, and dean of basic sciences and graduate studies as well as professor of pediatrics at Harvard Medical School in the US. From 1993 to 2006, Dr. Andrews was a biomedical research investigator at the Howard Hughes Medical Institute, also in the US. Her research is in iron homeostasis and mouse models of human diseases. Dr. Andrews received her Ph.D. in biology from the Massachusetts Institute of Technology in the US and her M.D. from Harvard Medical School. She completed her residency and fellowship trainings in pediatrics and hematology/oncology at Boston Children’s Hospital and the Dana-Farber Cancer Institute, both in the US, and served as an attending physician at Boston Children’s Hospital. Dr. Andrews also served as president of the American Society for Clinical Investigation. Additionally, she was elected as a fellow of the American Association for the Advancement of Science and to membership in the US National Academy of Sciences, the National Academy of Medicine, and the American Academy of Arts and Sciences. She serves on the council of the National Academy of Medicine and on the board of directors of the American Academy of Arts and Sciences.

Dimitri Azar

Dr. Dimitri Azar, M.D. is Non-Executive Independent Director of Novartis Inc. since February 2012. He qualifies as an independent Non-Executive Director. He is Dean of the College of Medicine and professor of ophthalmology, bioengineering and pharmacology at the University of Illinois at Chicago in the United States, where he formerly was Head of the Department of Ophthalmology and Visual Sciences. He sits on the Board of Trustees of the Chicago Ophthalmological Society and the Association of Research in Vision and Ophthalmology. Dr. Azar is Member of the American Ophthalmological Society and holds committee positions with the American Academy of Ophthalmology. Dr. Azar began his career at the American University Medical Center, Beirut, Lebanon, and completed his fellowship and residency training at the Massachusetts Eye and Ear Infirmary at Harvard Medical School in the United States. Dr. Azar practiced at the Wilmer Ophthalmologic Institute at The Johns Hopkins Hospital School of Medicine, then returned to the Massachusetts Eye and Ear Infirmary as director of the cornea and external disease. He became professor of ophthalmology with tenure at Harvard Medical School in 2003. Dr. Azar holds an Executive Master of Business Administration from the University of Chicago, Booth School of Business.

Ton Buechner

Mr. Ton Buechner is Non-Executive Independent Director of Novartis Inc. since February 23, 2016. Since 2012, Mr. Buechner has served as chairman and CEO of the executive board of Dutch multinational AkzoNobel. Prior to joining AkzoNobel, he spent almost two decades at the Sulzer Corporation in Switzerland, where he was appointed divisional president in 2001 and served as president and CEO from 2007 to 2011. Mr. Buechner’s early career was spent in the oil and gas construction industry, and included roles at Allseas Engineering in the Netherlands and at Aker Kvaerner in Singapore. He is a member of the supervisory board of Voith GmbH.

Srikant Datar

Dr. Srikant Datar, Ph.D., has been Non-Executive Independent Director of Novartis Inc. since 2003. He qualifies as Independent Non-Executive Director. He is Chairman of the Audit and Compliance Committee and was Member of the Risk Committee and the Compensation Committee at the Company. Dr. Datar has worked as an accountant and planner in industry, and as a professor at Carnegie Mellon University, Stanford University and Harvard University in the United States. His research interests are in the areas of cost management, measurement of productivity, product development, timebased competition, incentives and performance evaluation. He is the author of a number of scientific publications and has received several academic awards and honors. Dr. Datar has advised and worked with numerous companies in research, development and training. Dr. Datar is Arthur Lowes Dickinson Professor at the Graduate School of Business Administration at Harvard University. He is also Member of the Board of Directors of ICF International Inc. and of Stryker Corp., both in the United States, and of KPIT Cummins Infosystems Ltd., India. He graduated with distinction in mathematics and economics from the University of Bombay, India, in 1973. He is a Chartered Accountant and holds two Masters degrees and a Doctor of Philosophy (Ph.D.) from Stanford University, United States.

Elizabeth Doherty

Ms. Elizabeth (Liz) Doherty is Non-Executive Independent Director of Novartis Inc. since February 23, 2016. She is a non-executive director and chairman of the audit committee of Dunelm Group PLC in the United Kingdom, and a member of the supervisory board and audit committee of Corbion NV in the Netherlands. She is a fellow of the Chartered Institute of Management Accountants, a non-executive board member of the UK Ministry of Justice, and a non-executive board member of Her Majesty’s Courts and Tribunals Service in the UK. She previously served as a non-executive director and audit committee member at Delhaize Group in Belgium and Nokia Corp. in Finland, and as a non-executive director at SABMiller PLC in the UK.

Ann Fudge

Ms. Ann M. Fudge has been Non-Executive Independent Director at Novartis Inc. since February 26, 2008. She is Member of the Risk Committee as well as Corporate Governance and Nomination Committee of the Company. She is former Chairwoman and Chief Executive Officer of Young & Rubicam Brands. Before that, she served as President of the Beverages, Desserts and Post Division of Kraft Foods. Ms. Fudge serves on the Board of Directors of General Electric Co., on the Board of Directors of Unilever, United Kingdom /Netherlands and on the Board of Directors of Infosys, India. She is a trustee of the New York-based Rockefeller Foundation and the Atlanta-based Morehouse College, and Chairman of the United States Programs Advisory Panel of the Bill & Melinda Gates Foundation. Ms. Fudge is further Member of the Harvard University Corporation Committee on Finance. She also sits on the Board of the Council on Foreign Relations. Ms. Fudge received her Bachelors degree from Simmons College and her Masters of Business Administration degree from Harvard University Graduate School of Business in the United States.

Pierre Landolt

Dr. Pierre Landolt, Ph.D. serves as Non-Executive Independent Director at Novartis Inc. since 1996. He is Member of the Corporate Governance and Nomination Committee at the Company. From 1974 to 1976, he worked for Sandoz Brazil SA. In 1977, he acquired an agricultural estate in the semi-arid Northeast Region of Brazil and, over several years, converted it into a model farm in organic and biodynamic production. Since 1997, Dr. Landolt has been Associate and Chairman of AxialPar Ltda, Brazil, an investment company focused on sustainable development, with investments in fish farming, soybean for human consumption and organic vegetable. In 2000, he co-founded EcoCarbone SA, France, a company active in the design and development of carbon-sequestration processes in Asia, Africa, South America and Europe. In 2007, he co-founded Amazentis SA, Switzerland, a startup company active in the convergence space of medication and nutrition. He is a Member of the Board of Directors of Syngenta AG and a Partner with unlimited liabilities of the Swiss private bank Landolt & Cie. In Brazil, Dr. Landolt serves as President of the Instituto Fazenda Tamandua, the Instituto Estrela de Fomento ao Microcredito, AxialPar Ltda. and Moco Agropecuaria Ltda. In Switzerland, he is Chairman of Emasan AG and Vaucher Manufacture Fleurier SA, Vice Chairman of Parmigiani Fleurier SA, and is on the Board of the Syngenta Foundation for Sustainable Agriculture. He is Member of the Board of EcoCarbone SA, France, and Swiss Amazentis SA. He is also Vice Chairman of the Montreux Jazz Festival Foundation. Dr. Landolt graduated with a Bachelors degree in Law from the University of Paris-Assas.

Charles Sawyers

Dr. Charles L. Sawyers, M.D. has been Non-Executive Independent Director of Novartis Inc. since 2013. In the United States, Dr. Sawyers is chair of the Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center; professor of medicine and of cell and developmental biology at the Weill Cornell Graduate School of Medical Sciences; and an investigator at the Howard Hughes Medical Institute. He serves on U.S. President Barack Obama’s National Cancer Advisory Board, and is president-elect of the American Association of Cancer Research, and former president of the American Society for Clinical Investigation. He also is a member of the U.S. National Academy of Sciences and Institute of Medicine. Dr. Sawyers received his M.D. from the Johns Hopkins School of Medicine in the United States, and worked at the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles for nearly 18 years before joining Memorial Sloan-Kettering in 2006. He is cancer researcher; and co developed the Novartis cancer drug Gleevec/Glivec, and has received numerous honors and awards, including the Lasker- DeBakey Clinical Medical Research Award in 2009. He was program chair at cancer treatment and research institution; member of U.S. cancer advisory board; president-elect of organization; former president of medical honor society.

Andreas von Planta

Dr. Andreas von Planta, Ph.D. has been Non-Executive Independent Director at Novartis Inc. since February 28, 2006. He qualifies as an independent Non-Executive Director of the Company. He is Chairman of the Risk Committee, Member of the Audit and Compliance Committee, and Chairman of the Corporate Governance and Nomination Committee at the Company. He passed his bar examinations in Basel in 1982. Since 1983, he has been working for the law firm Lenz & Staehelin in Geneva, where he became a partner in 1988. His areas of specialization include corporate law, corporate finance, company reorganizations, and mergers and acquisitions. Mr. von Planta is Chairman of the Schweizerische National-Versicherungs-Gesellschaft AG and a Board Member of Holcim Ltd., both in Switzerland. He is also a Board Member of various Swiss subsidiaries of foreign companies and other nonlisted Swiss companies. He is Member of the Board of Editors of the Swiss Review of Business Law and former Chairman of the Geneva Association of Business Law. Mr. von Planta is Chairman of the regulatory board of the SIX Swiss Exchange AG. Mr. von Planta holds Lizentiat des Rechts (lic. iur., LLB) and Doctorote in Philosophy (Ph.D.) degrees from Universitaet Basel, Switzerland, and an Master of Laws (LL.M.) from Columbia University School of Law, New York, United States.

William Winters

Mr. William (Bill) T. Winters has been Non-Executive Independent Director of Novartis Inc. since 2013. Mr. Winters is chairman and Chief Executive Officer of Renshaw Bay, an alternative asset management and advisory company based in London. He is a former member of the UK Independent Commission on Banking, and served as co-Chief Executive Officer of JPMorgan’s investment banking business from 2003 to 2010. Mr. Winters received his bachelor’s degree from Colgate University and his Masters of Business Administration from the Wharton School at the University of Pennsylvania. He joined JPMorgan in 1983 and held management roles across several market areas and in corporate finance during his time there. Mr. Winters serves on the boards of Colgate University and the International Rescue Committee, both in the United States, and of the Young Vic Theatre and The Print Room, both in London. His leadership and Global experience include chairman and Chief Executive Officer of alternative asset management and advisory company; former co-Chief Executive Officer of investment banking at global financial services firm.

Samir Shah

Basic Compensation